The first doses of an experimental antiviral for hantavirus treatment are being dispatched to France, Spain and the Netherlands, the European Commission said on Thursday.
In the absence of a specific treatment for hantavirus, the European Medicines Agency identified favipiravir as the most plausible candidate for use under clinical trial or compassionate use protocols, the Commission said in a statement reported by Reuters.
